# To assess the effectiveness of Systane COMPLETE in improving meibomian gland score and in reducing symptoms of ocular dryness

## TL;DR

This study shows that Systane COMPLETE improves dry eye symptoms and objective measures in patients with mild to moderate dry eye disease.

## Contribution

The study demonstrates the effectiveness of a lipid-based nanoemulsion in improving meibomian gland function and dry eye symptoms.

## Key findings

- Significant improvements in tear breakup time, Schirmer’s test, and lipid layer thickness were observed.
- OSDI scores and corneal staining scores improved significantly after treatment.
- Meibomian gland score change was not statistically significant.

## Abstract

To assess the effectiveness of Systane COMPLETE in reducing symptoms of ocular dryness and improving Meibomian Gland (MG) Score in subjects with mild to moderate dry eye disease (DED).

A prospective, interventional, single-center, single-arm study was conducted including cases of mild to moderate DED. Participants were prescribed a topical lipid-based combination of propylene glycol (PG) and hydroxypropyl guar (HPG) (Systane® COMPLETE), administered four times daily for 30 days. Dry eye assessment parameters, Meibo score, and Ocular Surface Disease Index (OSDI) questionnaire responses were obtained before and after treatment.

A total of 105 cases with mild to moderate DED were included in the study. Statistically significant improvements were observed in tear breakup time (TBUT) (p<0.0001), Schirmer’s test (p<0.0001), lipid layer thickness (LLT) (p<0.0001), tear meniscus height (TMH) (p=0.0002), non-invasive breakup time (NIBUT) (p<0.0001), OSDI (p<0.0001), upper lid meibomian gland score (p=0.02), corneal staining score (p<0.0001). The change in Meibo score was not statistically significant (p=0.19).

A lipid-based nanoemulsion of PG–HPG helps in improving the objective parameters and symptoms of DED. Additionally, it may support improved meibomian gland function.